Stock 600789 SHANDONG LUKANG PHARMACEUTICAL CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Shandong Lukang Pharmaceutical Co.,Ltd.

Equities

600789

CNE000000P61

End-of-day quote Shanghai S.E.
Other stock markets
 03:30:00 27/06/2024 am IST 		5-day change 1st Jan Change
6.94 CNY -2.53% Intraday chart for Shandong Lukang Pharmaceutical Co.,Ltd. -4.80% -2.80%
29/05 China Approves Lukang Pharma's Anti-Asthma Injection MT
23/04 Shandong Lukang Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Shandong Lukang Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Shandong Lukang Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Lukang Pharmaceutical Gets Nod to Produce Parkinson's Disease Drug
MT
Lukang Pharmaceutical's Piperacillin Sodium, Tazobactam Sodium Injection Passes Regulatory Evaluation
MT
Lukang Pharmaceutical's Ampicillin Sodium and Sulbactam Sodium Pass Regulatory Evaluation
MT
Shandong Lukang Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Lukang Pharmaceutical's Ornidazole Tablets Passes Regulatory Evaluation
MT
Lukang Pharma Generic Hypertension Drug Passes Regulatory Evaluation
MT
Lukang Pharmaceutical's Cefaclor Granules Passes Chinese Drug Regulator's Evaluation
MT
Lukang Pharmaceutical's Cefixime Tablets Passes Regulator's Evaluation
MT
Shandong Lukang Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Lukang Pharmaceutical's Cefminox Sodium for Injection Passes Regulatory Evaluation
MT
Lukang Pharmaceutical's Cefaclor Capsules Passes Regulatory Evaluation
MT
Lukang Pharma's Cefazolin Sodium for Injection Passes Drug Regulator's Evaluation
MT
Lukang Pharma's Ampicillin Sodium for Injection Passes Regulatory Evaluation
MT
Shandong Lukang Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Lukang Pharma Gets Nod to Market Anti-Arthritis Drug Ingredient
MT
Shandong Lukang Pharmaceutical Raising 1.2 Billion Yuan to Fund Expansion Plans
MT
Lukang Pharma Gets Regulatory Nod for Anti-Pneumonia Drug
MT
Lukang Pharmaceutical Gets Approval for Diabetes Treatment Tablet
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 600789 Stock
  4. News Shandong Lukang Pharmaceutical Co.,Ltd.
  5. Highlights